PHILADELPHIA, July 02, 2025 (GLOBE NEWSWIRE) -- A federal securities fraud class action alleging that Virtu Financial Inc. (NYSE: VIRT), and certain of its officers failed to make proper disclosures to investors has survived a motion to dismiss and the Securities and Exchange Commission action against Virtu has reached a tentative settlement. Virtu shareholders who have continuously held Virtu shares since prior to November 7, 2018, can seek corporate reforms, the return of funds back to the company, and a ...

Core Viewpoint - A class action lawsuit has been filed against DoubleVerify Holdings, Inc. for alleged securities fraud and unlawful business practices [2][3]. Company Performance - On February 28, 2024, DoubleVerify lowered its revenue growth expectations for Q1 2024, leading to a stock price drop of $8.35 per share, or 21.3%, closing at $30.89 on February 29, 2024 [3]. - On May 7, 2024, the company cut its full-year 2024 revenue outlook due to reduced ad spending from customers, resulting in a stock price decline of $11.79 per share, or 38.6%, closing at $18.78 on May 8, 2024 [4]. - On February 27, 2025, DoubleVerify reported lower-than-expected Q4 2024 sales and earnings, with a stock price drop of approximately 36%, closing at $13.90 on February 28, 2025 [5]. Market Research Findings - On March 28, 2025, Adalytics Research, LLC released a report claiming that DoubleVerify's advertisement verification services are ineffective, stating that customers are billed for ad impressions served to bots [6]. - The Wall Street Journal reported that DoubleVerify frequently fails to detect nonhuman traffic, contradicting the company's claims of helping brands avoid serving ads to bot accounts [6].

LOS ANGELES, July 2, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Petco Health and Wellness Company, Inc. ("Petco" or "the Company") (NASDAQ: WOOF) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between January 14, 2021 and June 5, 2025, inclusive (the " ...

Core Viewpoint - A lawsuit has been filed against Iovance Biotherapeutics, Inc. and certain senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for melanoma and other solid tumor cancers [3]. - The company launched its key melanoma treatment, Amtagvi, in February 2024, administered at authorized treatment centers (ATCs) [3]. Allegations and Issues - The lawsuit alleges that Iovance misrepresented the effectiveness of its ATCs as a driver of demand for Amtagvi, while in reality, these centers faced long timelines for patient treatment and high patient drop-off rates due to ineffective patient identification and selection [4]. - Following disappointing financial results for Q1 2025, Iovance revised its full-year 2025 revenue guidance, citing slow treatment timelines and high patient drop-off as contributing factors [5]. Stock Performance - On May 8, 2025, Iovance's stock price fell over 44%, dropping from $3.17 per share to $1.75 per share the following day, in response to the negative news regarding its financial performance and operational challenges [6].

Core Viewpoint - A lawsuit has been filed against Fortrea Holdings Inc. and its senior executives for potential violations of federal securities laws, specifically related to the company's financial disclosures and performance claims [1][2]. Company Overview - Fortrea Holdings Inc. is a global contract research organization that provides biopharmaceutical product and medical device development solutions. It was spun off from Labcorp Holdings Inc. in June 2023 and entered into transition services agreements with Labcorp [3]. Allegations - The lawsuit alleges that Fortrea overstated the cost savings and margin improvements expected from exiting the transition services agreements, as well as the revenue from pre-spin projects [4]. Stock Performance - Following a report from Jefferies on September 25, 2024, which indicated that the anticipated cost savings were not as significant as previously thought, Fortrea's stock price fell by $2.73, or over 12%, from $22.21 to $19.48 [5]. - On March 3, 2025, Fortrea announced disappointing financial results for Q4 and the full year 2024, leading to a further decline in stock price by $3.47, or over 25%, from $13.85 to $10.38 [6].

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Compass Diversified Holdings and Compass Group Diversified Holdings, LLC (NYSE: CODI) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Compass you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/compass-diversified-holdings. Investors ...

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the management of Medicaid benefits during the COVID-19 pandemic [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092 [2]. - Investors who purchased Elevance common stock are encouraged to seek additional information and may request to be appointed to lead the case by July 11, 2025 [2]. Group 2: Background on Medicaid Management - Elevance provides health insurance plans, including contracts with states to administer Medicaid benefits [3]. - The federal government paused the review of Medicaid eligibility during COVID, which resumed in 2023, leading to increased acuity and utilization among Elevance's Medicaid members [3][5]. Group 3: Financial Impact and Stock Performance - Elevance had previously stated it was monitoring cost trends related to Medicaid redetermination, but the actual increase in acuity and utilization was not reflected in its financial guidance for 2024 [4][5]. - Following announcements of increased utilization and missed earnings expectations, Elevance's stock price declined significantly: a drop of $32.21 per share (nearly 6%) on July 17, 2024, and a further decline of $52.61 per share (nearly 11%) on October 17, 2024 [6][7].

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Hims & Hers, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action. Investors have until August 25, 2025, to ask th ...

Group 1 - Halper Sadeh LLC is investigating MRC Global Inc. for potential violations related to its sale to DNOW Inc. at a ratio of 0.9489 shares of DNOW for each share of MRC [1] - Big 5 Sporting Goods Corp. is being investigated for its sale to a partnership for $1.45 per share in cash [2] - The firm may seek increased consideration for shareholders and additional disclosures regarding the proposed transactions [3] Group 2 - Shareholders are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options at no charge [4] - Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, recovering millions for defrauded investors [4]

Company Overview - Hims & Hers Health, Inc. is a telehealth and online pharmacy company that provides prescription and over-the-counter medications, mental health services, and personal care products through a direct-to-consumer platform, connecting users with licensed healthcare professionals in the U.S. and the U.K. [3] Allegations and Impact - Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving Hims, stemming from allegations of providing potentially misleading business information to the investing public [1] - On April 29, 2025, Novo Nordisk announced it would sell its weight loss drug Wegovy through Hims' telehealth platform, but on June 23, 2025, Novo Nordisk terminated its partnership with Hims due to concerns about Hims' compliance with laws governing the sale and marketing of compounded drugs [4] - Following the termination of the partnership, Hims' stock price fell by $22.24 per share, or 34.63%, closing at $41.98 per share on June 23, 2025 [4]